[1] Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum VaccinImmunother.2016;12(6):1332-1342. doi:10.1080/21645515.2015.1108500
[2] Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):e223-e234. doi:10.1016/S2468-2667(20)30010-4
[3] Yusupov A, Popovsky D, Mahmood L, Kim AS, Akman AE, Yuan H. The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC. Am J Stem Cells. 2019;8(3):52-64. Published 2019 Dec 15.
[4] Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH; American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020;70(4):274-280. doi:10.3322/caac.21616